Close Menu

NEW YORK (GenomeWeb) – Most women with poorly differentiated breast cancer tumors and low risk scores from Genomic Health's Oncotype DX did not die from their disease five years after diagnosis, even though most of them were spared chemotherapy after receiving test results, data presented at the San Antonio Breast Cancer Symposium last week showed.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.